Title:
External cephalic version: success rates with and without nitrous oxide
Authors: Thoa K. Ha, MD1, Robyn Lamar, MD,
MPH2, Cinthia Blat, MPH2, Melissa G.
Rosenstein MD, MAS2
Address:
1Division of Maternal-Fetal Medicine, Department of
Gynecology and Obstetrics, Emory School of Medicine, Atlanta GA
2Division of Maternal-Fetal Medicine, Department of
Obstetrics, Gynecology and Reproductive Sciences, University of
California, San Francisco
Disclosure: None
Financial support: None
Presentation of data: Accepted for Society of Maternal Fetal Medicine
Annual Meeting February 11-16, 2019 in Las Vegas, NV
Corresponding author contact information:
Thoa K. Ha
69 Jesse Hill Jr Dr
Glenn Building, Room 406
Atlanta, GA 30303
Email:
thoakimha@gmail.com
Telephone: (650) 305-8589
Contribution to authorship:
This study was designed, directed and coordinated by T.H. and M.R. Data
analysis was performed by C.B. The manuscript was written by T.H. and
R.L. and commented by all authors.
Key words and phrases: external cephalic version, breech presentation,
malpresentation, vaginal delivery, nitrous oxide, obstetrics, cesarean
delivery, anesthesia
Abstract
Objective
To compare the conversion rate of non-cephalic to cephalic presentation
in ECV with and without nitrous oxide.
Design
A retrospective cohort study
Setting
Single, tertiary care institution between January 2016 and June 2017
Population
Women with singleton, term gestation ECVs identified via International
Classification of Diseases 9th Edition and 10thEdition, Clinical Modification diagnosis code with breech or
malpresentation. Pregnancies with preterm gestation, multi-fetal
gestation, abnormal placentation, and rupture of membranes were excluded
Methods
Logistic regression was performed to test whether nitrous oxide was
associated with successful conversion to cephalic presentation.
Main Outcomes
The primary outcome was successful rate of conversion to cephalic
presentation. The secondary outcome was the rate of vaginal delivery.
Results
During the study period, 167 women underwent ECV: 77 with nitrous oxide
and 90 without nitrous oxide. Of the 77 women who used nitrous oxide, 25
(32.5%) were successful and 17 of these women delivered vaginally
(68%). Of the women who underwent ECV without nitrous oxide, 29
(32.2%) successfully converted and 21 of these delivered vaginally
(72%). After controlling for confounders, the use of nitrous oxide had
no clinically or statistically significant difference on ECV success
rates (OR 1.08, 95% CI 0.52-2.23).
Conclusion
Nitrous oxide does not seem to affect conversion rate to cephalic
presentation in ECV. Further studies are needed to determine the impact
of nitrous oxide on women’s decision to undergo ECV and on patient
satisfaction and tolerability.
Funding
The authors received no financial support for the research, authorship,
and/or publication of this article.
Introduction
Cesarean delivery is one of the most common obstetric procedure in the
United States where almost one in three women are delivered surgically
1,2. Rising cesarean delivery rates are a major concern due to the
higher risk of maternal morbidity and mortality as well as substantial
health care cost in comparison to vaginal delivery. Breech presentation
occurs in 4% of term pregnancies and is a common indication for
cesarean delivery3. External cephalic version (ECV) is a technique of
applying manual pressure on the maternal abdomen to convert the fetus to
cephalic presentation. If successful, this reduces the incidence of
cesarean delivery and confers advantages in maternal recovery and
avoidance of surgical complications. For these reasons, the American
College of Obstetrics and Gynecology (ACOG) and the Society of Maternal
Fetal Medicine (SMFM) encourages ECV as a technique to prevent cesarean
delivery and reduce the risk of complications in subsequent
pregnancies3.
Variables associated with higher rates of successful conversion to
cephalic presentation include: multiparity, gestational age, fetal
position, placental location, and maternal habitus4-6 . There have been
several randomized control trials which demonstrate that higher success
rates of ECV are attributable to neuraxial anesthesia due to improved
tolerability of procedure7-10. We hypothesize that nitrous oxide, an
inhaled anesthetic, would improve the success rates of ECV to cephalic
presentation. We compared outcomes in a cohort of women with breech
presentation who underwent ECV with the use of nitrous oxide and without
the use of nitrous oxide. The primary outcome was successful conversion
to cephalic presentation and the secondary outcome was vaginal delivery.
Methods
A retrospective cohort analysis was performed on all ECVs identified
between January 2016 and July 2017 through a perinatal database of
delivery records at the University of California, San Francisco. This
dataset includes International Classification of Diseases 9th Edition
and 10th Edition, Clinical Modification (ICD-9-CM/
ICD-10-CM) diagnosis and procedure codes. Women with the following ICD 9
and ICD 10 codes or procedure codes were included in the study: maternal
care for breech presentation, not applicable or unspecified (O32.1XX0),
breech or other malpresentation successfully converted to cephalic
presentation, antepartum (652.13), breech presentation, antepartum
(652.23), breech or other malpresentation successfully converted to
cephalic presentation, delivered (652.11), breech presentation without
mention of version, unspecified as to episode of care (652.20).
Procedure codes include: PR anesthesia antepartum manipulation (01958);
anesthesia antepartum head manipulation (59412), external version
(59412), PR anesthesia antepartum manipulation (01958). The exclusion
criteria were: preterm gestation, multi-fetal gestation, abnormal
placentation, and rupture of membranes. Manual chart review of the
electronic medical record was performed to identify use of nitrous oxide
during ECV procedure, successful in conversion to cephalic presentation,
and mode of delivery. The primary outcome was successful conversion to
cephalic presentation and the secondary outcome was vaginal delivery.
Prenatal characteristics collected included maternal age, gestational
age at ECV, body mass index, parity, and fetal birthweight. Women were
consented prior to procedure and instructed not to eat at least 8 hours
prior to the procedure. All women were offered the option of ECV under
nitrous oxide prior to the procedure and the use of nitrous oxide was
based on the patient’s preference. Women in the nitrous oxide group
inhaled nitrous oxide in a 50:50 mix with oxygen that was patient
controlled and administered by an anesthesia provider present. A
tocolytic, terbutaline, was administered to all women within 30 minutes
prior to the procedure. Fetal heart tracing was used to monitor fetal
status and ultrasound was used to confirm fetal position before and
after the procedure. Women in the control group did not use nitrous
oxide or any other form of anesthesia or analgesia during the procedure.
Complications associated with ECV examined include: placenta abruption,
cord prolapse, hemorrhage and fetal demise. Severe maternal
complications secondary to nitrous oxide inhalation include: respiratory
distress, seizures, and maternal mortality.
The number of women with successful conversion to cephalic presentation
and spontaneous vaginal delivery after ECV were compared between the
group that utilized nitrous oxide and the group that did not utilize
nitrous oxide. Differences between treatment groups were compared using
the independent samples t-test or Wilcoxon rank sum as appropriate.
Categorical variables were compared by chi-square. Logistic regression
was performed to test whether nitrous oxide was associated with
successful conversion to cephalic presentation. Potential confounders
maternal age, gestational age, parity, pre-pregnancy BMI, and
birthweight were examined for association with ECV through bivariate
analysis and retained in the final model if p<0.02.
Pre-pregnancy BMI did not meet this criterion and was excluded from the
final model. All analyses were performed using SAS ver 9.4 (SAS
Institute, Cary, NC, USA). This study was approved by the Institutional
Review Board of the University of California San Francisco (UCSF).
Results
During the study period, 167 women underwent ECV: 77 women with the use
of nitrous oxide and 90 women without the use of nitrous oxide. Of the
77 women who underwent ECV with nitrous oxide, 25 (32.5%) women were
successfully converted to cephalic presentation and 17 of these women
delivered vaginally (68%) (►Fig. 1). Of the 90 women who underwent ECV
without nitrous oxide, 29 (32.2%) women were successfully converted to
cephalic presentation and 21 of these women delivered vaginally (72%).
Clinical characteristics of the participants are presented in Table 1.
Groups exposed to nitrous oxide and without exposure to nitrous oxide
had similar parity, median gestational age at ECV (37.3 weeks versus
37.3 weeks), median pre-pregnancy body mass index (21.9
kg/m2 versus 22.9 kg/m2), and median
birthweight (3.2 kg versus 3.3 kg). After controlling for confounders,
nitrous oxide was not associated with higher conversion to cephalic
presentation (adjusted odds ratio [aOR] 1.08, 95% CI 0.52-2.23).
Successful conversion to cephalic presentation was more likely when ECV
was performed later in the pregnancy (OR 2.26), in women who were
nulliparous (OR 3.33) and for higher estimate fetal weight (OR 1.11)
(►Table 2). Higher maternal age was associated with successful
conversion on bivariate analysis, but this did not persist after
covariate adjustment.
There were no significant differences in the rate of complications
associated with ECV in the rate of emergent cesarean sections or adverse
perinatal outcomes: placenta abruption, cord prolapse, hemorrhage and
fetal demise. Furthermore, there were no severe maternal complications
secondary to nitrous oxide inhalation.
Discussion
Main findings
Our study compared women with cephalic presentation underdoing ECV with
the use of nitrous oxide and without the use of nitrous oxide. Our
findings show that nitrous oxide was not associated with improved
success to conversion to cephalic presentation. As expected, we report a
high rate of spontaneous vaginal delivery, nearly 72% and 68% in women
who had successful ECV in the nitrous oxide group and the without
nitrous oxide group respectively. There was also a low rate of
complications of approximately <1% that was consistent with
previous reports 11-12 .
This data contributes to the understanding of analgesia use in ECV,
particularly nitrous oxide. This may further support that analgesia does
not contribute to adverse outcomes secondary to potentially increased
provider pressure during the procedure. Our data reinforces that nitrous
oxide has a safe profile as there were no severe maternal or fetal
complications.
Strength and Limitations
In interpretation of the findings of this study, there are some
important considerations. The data on nitrous oxide use in ECV is
limited. There are a few studies which showed that the use of nitrous
oxide in ECV did not show a difference in success rate in conversion to
cephalic presentation compared to without nitrous oxide13,14. While our
study is retrospective, it is one of the few studies in the literature.
Furthermore, this study was conducted at a single, tertiary care center,
which may limit its generalizability. However, the major strength of
this study is that both groups were well matched in terms of possible
confounders. Additionally, both cohorts of women had a mean age of
thirty-three and mainly nulliparous which may generalize well to
institutions with similar populations. We acknowledge that our success
rate differs from reported success rate of up to 50-60%, 3, 14. This
may be due to the larger number of nulliparous women in both cohorts
(79.2% with nitrous oxide vs 78.9% without nitrous oxide) which may
contribute to a lower success rate.
Nulliparity
has been more often associated with unsuccessful ECV 16-18. However, if
successfully converted to cephalic, the majority of these women are more
likely to have vaginal delivery in both cohorts, 72% with nitrous oxide
versus 68% without nitrous oxide. The ACOG encourages ECV as the
first-line approach in pregnancies as an effective preventive tool for
breech indicated cesarean deliveries; however, only approximately 70%
of eligible women are offered ECV3. Therefore, improved utilization of
this technique may provide greater opportunities to lower the rate of
cesarean deliveries. While nitrous oxide does not seem to improve the
success rate, it may be an effective mechanism for pain control which
would allow more women to participate in the procedure. Due to its
safety profile, providers may consider offering nitrous oxide as a
method for pain management for candidates contemplating ECV. While safe,
nitrous oxide is currently not as widely available in many facilities.
This may be due to the lack of anesthesia personnel, facility
requirements, or inexperience. Cesarean delivery is a reasonable mode of
delivery for cephalic pregnancies; however, cesarean delivery incurs a
higher risk of maternal morbidity. Therefore, external cephalic version
may be a useful option particularly in low resourced settings where
vaginal breech delivery or cesarean delivery may not be available or
safe.
Interpretations
The decision to undergo external cephalic version may be difficult for
many women. In a study performed by Nassar et. al. in 2007 which
assessed women’s informed decision making after randomized to a decision
aid, a workbook detailing risk and benefits, versus control, women who
received the decision aid had 74% intention to undergo ECV versus 64%
in the control group. The cohort with additional information via the
workbook report lower decisional conflict, increased knowledge, and
greater satisfaction with their decision. Importantly, for women where
pain control is a major deterrent for ECV, the availability of nitrous
oxide may significantly impact women’s willingness to attempt the
procedure. Lastly, ECV has been an underutilized technique to combat the
rising rates of cesarean delivery and maternal morbidity and mortality.
Moreover, this may be a critical area to target for the prevention of
primary cesarean deliveries as these women are more than 90% likely to
have repeat cesarean deliveries in subsequent pregnancies. Lastly,
nitrous oxide may be able to offer another safe option for pain control
for women in an area where the options are limited. However, further
studies are needed to examine the impact of analgesia on women’s
decision to undergo ECV.
Conclusion
In summary, our study shows that use of inhaled nitrous oxide during ECV
is not associated with improved success in conversion to cephalic
presentation when compared to without use of nitrous oxide. We highlight
that while ECV remains an important modality for preventing cesarean
delivery in pregnancies with malpresentation, it is important to inform
women that the use of nitrous oxide does not seem to independently
improve conversion to cephalic presentation.
Disclosure of interests
The authors have no conflicts of interests to disclose. Completed
disclosure of interest forms are available to view as online supporting
information
Contribution to authorship
This study was designed, directed and coordinated by T.H. and M.R. Data
analysis was performed by C.B. The manuscript was written by T.H. and
R.L. and commented by all authors.
Funding
The authors received no financial support for the research, authorship,
and/or publication of this article.
Details of ethics approval
This study was approved by the Institutional Review Board of the
University of California San Francisco number T17-2289, reference number
196744 from 8/16/2017 to 8/16/2016
Acknowledgement
We thank the patients and their families.
References:
- Blanchette, H. The rising Cesarean Delivery Rate in America: What are
the Consequences? Obstet Gynecol 2011 Sept; 118(3): 687-690
- FastStats https://www.cdc.gov/nchs/fastats/delivery.htm
- External cephalic version. Practice Bulletin No. 161. American College
of Obstetricians and Gynecologists. Obstet Gynecol 2016; 127: 54–61.
- Ben-Meir A, Erez Y, Sela HY, et al. Prognostic parameters for
successful external cephalic version. J Matern Fetal Neonatal
Med , 21 (9) (2008), 660-662
- Kok M, Cnossen J, Gravendeel L, et al. Clinical factors to
predict the outcome of external cephalic version: a metaanalysis.Am J Obstet Gynecol , 1999 (6) (2008) 630.e1-7
- Hutton EK, Hannah ME, Ross SJ, et al. The Early External
Cephalic Version (ECV) 2 trial: an international multicentre
randomised controlled trial of timing of ECV for breech pregnancies.
BJOG, 118 (5) (2011) 564-577
- Goetzinger KR, Harper LM, Tuuli MG, et al. Effect of regional
anesthesia on the success rate of external cephalic version: a
systematic review and meta-analysis. Obstet
Gynecol , 118 (5) (2011) 1137-1144
- Sullivan JT, Grobman WA, Bauchat JR, et al. A randomized
controlled trial of the effect of combined spinal-epidural analgesia
on the success of external cephalic version for breech presentation.Int J Obstet Anesth , 18 (4) (2009), 328-334
- Weiniger CF, Ginosar Y, Elchalal U, et al. Randomized
controlled trial of external cephalic version in term multiparae with
or without spinal analgesia. Br J
Anaesth , 104 (5) (2010),613-618
- Mancuso KM, Yancey MK, Murphy JA, et al. Epidural analgesia for
cephalic version: a randomized trial. Obstet
Gynecol , 95 (5) (2000) 648-651
- Rodgers R. External cephalic version is associated with a low
complication rate. BJOG . 2019 Mar;126(4):493-499
- Rodgers R, Beik
N, Nassar
N, Brito I, de Vries B. Complications of external cephalic version: a
retrospective analysis of 1121 patients at a tertiary hospital in
Sydney. BJOG . 2017 Apr;124(5):767-772
- Burgos J, Cobos P, Osuna C, de Mar Centeno M, Fernández-Llebrez L,
Astorquiza TM, Melchor JC. Nitrous oxide for analgesia
in external cephalic version at term: prospective
comparative study. J Perinat Med . 2013 Nov;41(6):719-23
- Dochez V, Esbelin J, Misbert E et al. Effectiveness of Nitrous Oxide
in External Cephalic Version on Success Rate: A Randomized Trail.Acta Obstet Gynecol Scand , 99 (3). 391-398
- Hofmeyr GJ, Kulier R, West HM. External cephalic version for
breech presentation at term. Cochrane Database Syst Rev . 2015
Apr 1;(4)
- Lim, S and Lucero, J. Obstetric and Anesthetic Approaches to External
Cephalic Version.Anesthesiology
Clinics. 35 (1) March 2017. 81-94
- Newman RB, Peacock BS, VanDorsten JP, Hunt HH. Predicting success of
external cephalic version. Am J Obstet Gynecol 1993;169:245–9
- Tan GW, Jen SW, Tan SL, Salmon YM. A prospective randomised controlled
trial of external cephalic version comparing two methods of uterine
tocolysis with a non-tocolysis group. Singapore Med J1989;30:155–8.
- Wong WM, Lao TT, Liu KL. Predicting the success of external cephalic
version with a scoring system. A prospective, two-phase study. J
Reprod Med 2000;45:201–6.